

# HEALTHCARE MONTHLY

**APRIL 2024** 

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma Healthcare Services Life Sciences / Diagnostics



**Medical Devices** 

### **HEADLINE TRANSACTIONS**

TARGET

ACOUIROR

ACQUISITION SYNOPSIS



Life Sciences / Diagnostics





- Ingersoll Rand, Inc. (NYSE:IR) has entered a definitive agreement to acquire ILC Dover LP from New Mountain Capital, LLC
- ILC Dover designs and manufactures engineered flexible protective products for the biopharmaceutical, pharmaceutical, medical device and aerospace end markets
- Ingersoll Rand provides air, gas, liquid and solid flow creation technologies and services; it operates through two business segments: Industrial Technologies & Services and Precision & Science Technologies
- Total Consideration: \$2.3 billion cash; \$75 million earnout






- AstraZeneca plc (LON:AZN) has entered a definitive agreement to acquire Fusion Pharmaceuticals, Inc. (NASD:FUSN)
- Fusion Pharmaceuticals develops radiopharmaceuticals intended to treat prostate-specific membrane antigens and solid tumors
- AstraZeneca discovers, develops and manufactures prescription medicines serving primary care and specialty care physicians
- Total Consideration: \$2.1 billion cash
- Per Share Price Premium: 13.8%





- $\bullet \quad \text{Novo Nordisk A/S (NYSE:NVO) has entered a definitive agreement to acquire Cardior Pharmaceuticals, GmbH}\\$
- Cardior discovers and develops therapies targeting non-coding RNAs capable of alleviating heart disease symptoms including cardiac hypertrophy, fibrosis, impaired contractility and reduced vascularization
- · Novo Nordisk discovers, develops and distributes pharmaceuticals targeting diabetes, obesity and rare diseases
- Total Consideration: \$1.1 billion cash






- · AstraZeneca plc (LON:AZN) has entered a definitive agreement to acquire Amolyt Pharma SAS from Sofinnova Partners
- · Amolyt Pharma develops therapeutic peptides for endocrine and metabolic diseases including hypoparaythyroidism
- AstraZeneca discovers, develops and manufactures prescription medicines serving primary care and specialty care physicians
- Total Consideration: \$800 million cash; \$250 million earnout




## HEALTHCARE GROWTH & VALUATION TRENDS


#### **Enterprise Value / LTM Revenue**




#### **Enterprise Value / LTM EBITDA**



#### LTM Revenue Growth



#### LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

#### LTM Stock Price Index





### SELECTED HEALTHCARE TRANSACTIONS


Target		Acquiror		BioTech / Pharma Transactions
Landos Biopharma, Inc. (NASD:LABP)		AbbVie (NYSE:ABBV)		Landos discovers and develops oral therapeutics targeting autoimmune and metabolic diseases including ulcerative colitis Total Consideration: \$138 million cash; \$75 million earnout Per Share Price Premium: 46.4%
IFM Therapeutics, LLC		Novo Nordisk A/S (NYSE:NVO)		IFM develops small molecule therapeutics targeting autoimmune diseases, inflammatory disorders and cancer
Gamida Cell (NASD:GMDA)		Highbridge Capital Management, Ll	LC	Gamida Cell develops curative cell therapy candidates for patients with solid tumors, blood cancers and other serious diseases
Target	Acq	Acquiror		fe Sci / Diagnostics Transactions
NanoString Technologies, Inc. (OTC:NSTGQ)	Patient Square Capital, LP		the	anoString Technologies develops, manufactures and immercializes instruments, consumables and services for e profiling of genes and proteins in scientific and clinical search tal Consideration: \$220 million cash
Poly Scientific R&D	•			oly Scientific R&D manufactures pathology stains, tissue introls, reagents and paraffin for pathology laboratories
Corporation		en manager		

#### Selected TM Capital Healthcare Experience









Target	Acquiror	Medical Device Transactions
Advanced Cooling Therapy, Inc. d/b/a Attune Medical	Haemonetics Corporation (NYSE:HAE)	Attune Medical manufactures FDA-cleared temperature regulation devices that protect the esophagus during cardiac ablation
DermLite LLC (DW Healthcare Management, LLC)	FotoFinder Systems GmbH (EMZ Partners SAS)	DermLite manufactures and supplies handheld dermatoscopes for skin visualization and early skin cancer detection
Péters Surgical SASU (Eurazeo SE)	Advanced Medical Solutions plc	Péters Surgical manufactures and supplies specialty surgical sutures, hemostatic clips, internal cyanoacrylate devices and other disposable surgical supplies for hospitals, clinics and medical centers

#### TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



John Dean Principal jdean@tmcapital.com 404.995.6234



Paul Smolevitz Managing Director psmolevitz@tmcapital.com 212.809.1416



Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232